Australia's Artrya climbs as FDA clears Salix for US sale

Artrya

28/03/2025 02:04

** Shares of medical technology co Artrya AYA.AX rise 9.4% to A$0.875

** Stock hits its highest level since January 20

** Co secures U.S. Food and Drug Administration (FDA) clearance for commercial sale of Salix Coronary Anatomy in the United States

** Salix is the first point of care approach for assessing coronary artery disease, says co

** About 1.9 million shares change hands, 9.7 times the 30-day average volume of shares

** Stock up 50.9% this year, as of last close

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com;))